Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02921412 · ClinicalTrials.gov registry record · NA

Performance of Fanfilcon A Toric Lenses After at Least One Month Wearing Enfilcon A Toric Lenses

A NA study of Astigmatism, sponsored by CooperVision.

Completed
Registry status
NA
Development phase
37
Enrollment target
4
Study locations

NCT02921412: Completed NA study of Astigmatism, sponsored by CooperVision.

NCT02921412 is a NA study of Astigmatism that has completed, run by CooperVision. The registered enrollment target is 37 participants, below the 105-participant average among 31 other Astigmatism trials with a reported enrollment target (65% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02921412, a NA study of Astigmatism, has completed, sponsored by CooperVision.

COMPLETED
Registry status
NA
Development phase
37 participants
Enrollment target
4
Study locations

Study Summary

This is a prospective, multi-center, subject-masked, bilateral, daily wear, two-month dispensing study

Primary Outcome

High contrast distance visual acuity is measured by LogMAR.

Conditions Studied

Astigmatism

Interventions

  • DEVICE fanfilcon A

Study Locations (4)

Florida

  • Hospital Contact Lens Service - Miami

New Jersey

  • Debbie Kim - Closter

New York

  • West Village Eyecare - New York

Washington

  • Spokane Eye Clinic - Spokane

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2016-10-01
Est. Completion 2017-03-21
Phase NA
CooperVision

64 total trials

What the finished NCT02921412 record still lists

NCT02921412 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 105-participant average among 31 other Astigmatism trials with a reported enrollment target (65% lower).

The record links to 1 condition, with Astigmatism appearing as the primary indexed condition, and to 1 intervention - of which fanfilcon A is the first listed.

NCT02921412 reports a single indexed study location in Florida, New Jersey, New York.

Frequently Asked Questions

What is clinical trial NCT02921412 about?

NCT02921412 is a clinical study titled "Performance of Fanfilcon A Toric Lenses After at Least One Month Wearing Enfilcon A Toric Lenses". This is a prospective, multi-center, subject-masked, bilateral, daily wear, two-month dispensing study

What is the current status of trial NCT02921412?

This trial is currently completed. It is a NA study. The enrollment target is 37 participants. The study started on 2016-10-01. Estimated completion is 2017-03-21.

What conditions does trial NCT02921412 study?

This clinical trial studies the following conditions: Astigmatism.

What interventions are being tested in trial NCT02921412?

The interventions under investigation include: fanfilcon A (DEVICE).

Who is sponsoring clinical trial NCT02921412?

This trial is sponsored by CooperVision, which has 64 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02921412 being conducted?

This trial has 4 study locations across Florida, New Jersey, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Astigmatism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02921412's enrollment target sits among peer trials

37 25th of 31 higher than 7 of 31 other Astigmatism trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Astigmatism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02800486 · 37 participants · Phase 2

    Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

  • NCT03173937 · 37 participants · Phase 1

    Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome

  • NCT03295227 · 37 participants · Phase 1

    Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

  • NCT03401047 · 37 participants · Early Phase 1

    Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02921412, the US trial registry maintained by the National Library of Medicine. NCT02921412 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.